|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2009-11-11
|
|
pubmed:abstractText |
Only a few clinical trials have been conducted in patients with advanced pancreatic cancer after failure of first-line gemcitabine-based chemotherapy. Therefore, there is no current consensus on the treatment of these patients. We conducted a randomised phase II study of the modified FOLFIRI.3 (mFOLFIRI.3; a regimen combining 5-fluorouracil (5-FU), folinic acid, and irinotecan) and modified FOLFOX (mFOLFOX; a regimen combining folinic acid, 5-FU, and oxaliplatin) regimens as second-line treatments in patients with gemcitabine-refractory pancreatic cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin,
http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Leucovorin,
http://linkedlifedata.com/resource/pubmed/chemical/Organoplatinum Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/gemcitabine,
http://linkedlifedata.com/resource/pubmed/chemical/irinotecan,
http://linkedlifedata.com/resource/pubmed/chemical/oxaliplatin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1532-1827
|
|
pubmed:author |
pubmed-author:GilG JGJ,
pubmed-author:HwangJ YJY,
pubmed-author:KimJ-EJE,
pubmed-author:KimM-HMH,
pubmed-author:KimT WTW,
pubmed-author:LeeJ SJS,
pubmed-author:LeeS KSK,
pubmed-author:LeeS SSS,
pubmed-author:LroJ BJB,
pubmed-author:MOER HRH,
pubmed-author:OhY JYJ,
pubmed-author:ParkD HDH,
pubmed-author:SeoD WDW
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
17
|
|
pubmed:volume |
101
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1658-63
|
|
pubmed:dateRevised |
2010-11-22
|
|
pubmed:meshHeading |
pubmed-meshheading:19826418-Adult,
pubmed-meshheading:19826418-Aged,
pubmed-meshheading:19826418-Antimetabolites, Antineoplastic,
pubmed-meshheading:19826418-Antineoplastic Agents,
pubmed-meshheading:19826418-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19826418-Camptothecin,
pubmed-meshheading:19826418-Deoxycytidine,
pubmed-meshheading:19826418-Disease-Free Survival,
pubmed-meshheading:19826418-Drug Resistance, Neoplasm,
pubmed-meshheading:19826418-Female,
pubmed-meshheading:19826418-Fluorouracil,
pubmed-meshheading:19826418-Humans,
pubmed-meshheading:19826418-Leucovorin,
pubmed-meshheading:19826418-Male,
pubmed-meshheading:19826418-Middle Aged,
pubmed-meshheading:19826418-Organoplatinum Compounds,
pubmed-meshheading:19826418-Pancreatic Neoplasms,
pubmed-meshheading:19826418-Prognosis,
pubmed-meshheading:19826418-Survival Rate,
pubmed-meshheading:19826418-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.
|
|
pubmed:affiliation |
Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 138-736, Korea.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
